Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000905148-25-002171
Filing Date
2025-06-17
Accepted
2025-06-17 17:48:02
Documents
2
Period of Report
2025-06-13

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 3769
2 magovcevic-liebisch_poa.htm EX-24 11824
  Complete submission text file 0000905148-25-002171.txt   17151
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address
Magovcevic-Liebisch Ivana (Reporting) CIK: 0001279281 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41551 | Film No.: 251054507

Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Issuer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)